Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 3, 2006, Pages 1287-1292

  Murphey, Laine J ^a   Malave, Hector A ^a   Petro, Jeff ^a   Biaggioni, Italo ^a   Byrne, Daniel W ^b   Vaughan, Douglas E ^a   Luther, James M ^a   Pretorius, Mias ^a,c   Brown, Nancy J ^a,d  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; BRADYKININ 1-5; DRUG METABOLITE; ENALAPRILAT; GAMMA THROMBIN; THROMBIN; THROMBIN RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD FLOW; BLOOD SAMPLING; BRACHIAL ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME RELEASE; FEMALE; FIBRINOLYSIS; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOCYTE AGGREGATION; VASODILATATION; VENOUS BLOOD;

ADULT; BRADYKININ; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FETUS; FIBRINOLYSIS; HUMANS; MALE; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBIN;

EID: 33747607036     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.104026     Document Type: Article

References (36)

1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828.
2. Bouchie JL, Hansen H, and Feener EP (1998) Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 18:1771-1779.
3. Brosnihan KB, Li P, and Ferrario CM (1996) Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27:523-528.
4. 2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 102:2190-2196.
5. Brown NJ, Gainer JV, Stein CM, and Vaughan DE (1999) Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 33:1431-1435.
6. Colman RW and Schmaier AH (1997) Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90:3819-3843.
7. Ferreira SH and Vane JR (1967) The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemother 30:417-424.
8. Freeman EJ, Chisolm GM, Ferrario CM, and Tallant EA (1996) Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28:104-108.
9. Gainer JV, Morrow JD, Loveland A, King DJ, and Brown NJ (1998) Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339:1285-1292.
10. Hasan AAK, Amenta S, and Schmaier AH (1996) Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of α-thrombin-induced platelet activation. Circulation 94:517-528.
11. Hasan AAK, Rebello SS, Smith E, Srikanth S, Werns S, Driscoll E, Faul J, Brenner D, Normolle D, Lucchesi BR, et al. (1999) Thrombostatin inhibits induced canine coronary thrombosis. Thromb Haemost 82:1182-1187.
12. Hasan AAK, Warnock M, Nieman M, Srikanth S, Mahdi F, Krishnan R, Tulinsky A, and Schmaier AH (2003) Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. Am J Physiol 285:H183-H193.
13. Hokanson DE, Sumner DS, and Strandness DEJ (1975) An electrically calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans Biomed Eng 22:25-29.
14. Jiang YJ, Wu JM, Hua Y, Keep RF, Xiang JM, Hoff JT, and Xi GH (2002) Thrombin-receptor activation and thrombin-induced brain tolerance. J Cerebr Blood Flow Metab 22:404-410.
15. Kerins DM, Hao Q, and Vaughan DE (1995) Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Investig 96:2515-2520.
16. Labinjoh C, Newby DE, Dawson P, Johnston NR, Ludlam CA, Boon NA, and Webb DJ (2000) Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res 47:707-714.
17. Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, and Webb DJ (2001) Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol 38:1402-1408.
18. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 105:771-772.
19. Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, and Kinoshita M (2001) Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 37:1565-1570.
20. Morinelli TA, Webb JG, Jaffa AA, Privitera PJ, and Margolius HS (2001) A metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the deleterious effects of lipopolysaccharide in rats. J Pharmacol Exp Ther 296:71-76.
21. Murphey LJ, Eccles WK, Williams GH, and Brown NJ (2004) Loss of sodium modulation of plasma kinins in human hypertension. J Pharmacol Exp Ther 308:1046-1052.
22. Murphey LJ, Gainer JV, Vaughan DE, and Brown NJ (2000a) Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 102:829-832.
23. Murphey LJ, Hachey DL, Oates JA, Morrow JD, and Brown NJ (2000b) Metabolism of bradykinin in vivo in humans: Identification of BK1-5 as a stable plasma peptide metabolite. J Pharmacol Exp Ther 294:263-269.
24. Murphey LJ, Hachey DL, Vaughan DE, Brown NJ, and Morrow JD (2001) Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid- chromatographic tandem mass spectrometric assay. Anal Biochem 292:87-93.
25. Nieman MT, Pagan-Ramos E, Warnock M, Krijanovski Y, Hasan AA, and Schmaier AH (2005) Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4. FEBS Lett 579:25-29.
26. Nieman MT, Warnock M, Hasan AAK, Mahdi F, Lucchesi BR, Brown NJ, Murphey LJ, and Schmaier AH (2004) The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J Pharmacol Exp Ther 311:492-501.
27. Pearson TC and Guthrie DL (1982) Trapped plasma in the microhematocrit. Am J Clin Pathol 78:770-772.
28. Pretorius M, McFarlane JA, Vaughan DE, Brown NJ, and Murphey LJ (2004) Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass. Clin Pharmacol Ther 76:379-387.
29. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, and Hennekens CH (1992) Baseline fibrinolytic state and the risk of future venous thrombosis: A prospective study of endogenous tissue plasminogen activator and plasminogen activator inhibitor. Circulation 85:1822-1827.
30. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, and Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Investig 86:1343-1346.
31. Smith D, Gilbert M, and Owen WG (1985) Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66:835-839.
32. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ETA, DeLago A, Wilmer C, Topol EJ, and the CREDO Investigators (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. J Am Med Assoc 288:2411-2420.
33. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, et al., and the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346:957-966.
34. Topol EJ (2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 357:1905-1914.
35. Vanhoutte PM (1989) Endothelium and control of vascular function: State of the art lecture. Hypertension 13:658-667.
36. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, and Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342:145-153.